bd@krishbiotech.com +91 33 2582-4472

Scientific Team

Dr. Imran Khan, M.V.Sc, D.M.M., Director-Toxicology

Imran Khan has over 15 years of experience in the core area of Animal Breeding and Toxicology. He is basically a veterinarian with masters (M.V.Sc.) in Veterinary Pharmacology and Toxicology. He has enriching experience inCRO as well as Pharmaceutical industry by virtue of his previous association with CROs like Jai Research Foundation, RCC Laboratories India Pvt. Ltd. (then sister concern of RCC Switzerland and later Harlan Ltd.), Systems Biology Worldwide (a Finnish CRO) and Pharmaceutical Companies like Glenmark Pharmaceuticals Ltd., BBRC (Biocon-Bristol-Myers Squibb Research Centre) and Piramal Enterprises Limited.

He was instrumental in setting up the labs and operations of GLP and has worked according to Netherlands, Swiss & Indian GLP. He has to his credit getting GLP certification for at least three labs right from the scratch. He is instrumental in setting up of CPCSEA and AAALAC compliant animal facilities.

He is an accomplished scientist and has contributed immensely to the development of Pharmaceutical and Agrochemical compounds by conducting regulatory toxicity studies up to 90-days duration for agrochemicals, non-clinical development and safety profiling of pharmaceutical INDs, Safety Pharmacology and different Disease Models for the discovery projects, with many studies submitted to and accepted by different regulatory authorities. He has distinction of having bred animals for the carcinogenicity study and also to work in the same study as study personal.

Raghuram Anupindi, M. Pharm., Ph.D., Director- Drug Discovery

Raghuram Anupindi has about 24 Years of experience in non-clinical Pharmacology in Drug Discovery and development. During this period, he worked in various therapeutic areas, such as diabetes and metabolic disorders, asthma, pain and inflammation. He played instrumental role in taking six molecules from non-clinical stage to different stages of clinical development, highest being successful completion of phase 2 with a DPP-IV inhibitor for treatment of type 2 diabetes. He has good experience in filing INDs with USFDA, schedule Y submissions with DCGI and conducting bioavailability and bioequivalence studies for various solid dosage forms.

He began his career in R&D at Cadila Healthcare Ltd /Zydus Cadila, Ahmedabad and worked for 8 years before moving to Glenmark Pharmaceuticals Research Centre, Mumbai, where he served for 12 years, working extensively on various projects /targets in drug discovery. At both these organizations he played an important role in establishment of labs, animal house, and other infrastructure for the new R&D centres. Prior to joining industry, he taught undergraduate and diploma students of Pharmacy for a couple of years.

Raghuram Anupindi obtained his bachelors degree in Pharmacy from University College of Pharmaceutical Sciences, Kakatiya University, Warangal, in the state of Telangana and Masters and Ph.D. degrees from Dept. Pharmaceutical Technology, Jadavpur University, Kolkata.

  • 
Download Brochure
  • Career
  • Feedback
T-1, QK-17 (Part) WBIIDC, Phase III,
Kalyani, Nadia, West Bengal 741 235 ,INDIA

+91 33 2582-4472